Cyclic gomesin as a scaffold for stabilising anticancer peptides and targeting melanoma cells
Sira Defaus Fornaguera·Sonia Troeira Henriques·Aurélie H. Benfield·Olivier Cheneval·Yen‐Hua Huang·Angeline Chan·Nicole Lawrence·David Andreu Martinez
Cyclic peptides are increasingly recognised as a therapeutic modality for modulating intracellular protein–protein interactions (PPIs), including those considered ‘undruggable’ by small molecules or biologics. Cyclic gomesin (cGm), an 18-residue β-hairpin peptide containing two disulfide bonds and a cyclised backbone, combines high chemical stability with amphipathic character that promotes selective interaction with negatively charged cancer cell membranes. We previously showed that cGm enters